NCT01853085

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,830 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.

Conditions

• Glaucoma, Primary Open Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Bimatoprost Ophthalmic Solution	Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.

Timeline

• Start date: 2013-04-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2013-05-14
• Last updated: 2019-04-19
• Results posted: 2015-05-28

Locations

1 site across 1 country: Germany